Loading...
•
Dec 31, 2020
Evofem Biosciences Q4 2020 Earnings Report
Evofem Biosciences reported financial results for Q4 2020, marked by the U.S. commercial launch of Phexxi and increase in consumer awareness.
Key Takeaways
Evofem Biosciences reported net product sales of $170,000 for the fourth quarter of 2020, their first full quarter of product sales after launching Phexxi. The company's "Get Phexxi" DTC campaign generated over 115 million views in its first two weeks, leading to increased consumer awareness.
"Get Phexxi" generated over 115 million views across all media platforms in its first two weeks, leading to an increase in consumer awareness of Phexxi and in telehealth activity.
More than 2,650 healthcare providers have prescribed Phexxi since launch.
First quarter 2021 Phexxi unit shipments to wholesalers are on track to exceed full-year 2020 levels.
Secured a $25 million strategic investment from Adjuvant Capital at a premium to market, with proceeds earmarked to fund the pivotal EVOGUARD trial and expand global market access for Phexxi.
Evofem Biosciences
Evofem Biosciences
Evofem Biosciences Revenue by Segment
Revenue by Segment
Net Product Sales Revenue
CapyFin.com Forward Guidance
Evofem Biosciences' forward guidance was not included in this report.